Newcastle Clinical Trials Unit



SETS aHUS: Stopping Eculizumab Treatment Safely in aHUS - Multicentre, open label, prospective, single arm study of the safety and impact of eculizumab withdrawal in patients with atypical haemolytic uraemic syndrome

  • Study stage: Follow-up
  • Sponsor: The Newcastle upon Tyne Hospitals NHS Foundation Trust
  • Funder: NIHR HTA
  • Therapeutic area: Renal and Urogenital
  • Type of study: CTIMP (Rare disease)

Aim: To establish an evidence base for an alternative treatment strategy for patients with aHUS that includes the use of Eculizumab to establish remission, safe withdrawal of treatment and the reintroduction of Eculizumab in those patients who relapse. 

Primary outcome:

To determine the safety of Eculizumab withdrawal in patients with Ahus


  • Population: Adults and Paediatrics
  • Clinical Phase: Phase IIb
  • Design: Cohort
  • Setting: Secondary care